A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab.

Published in: Current medical research and opinion (2022)

. This evidence may help guide providers, payers, and patients in shared decision-making conversations around best treatment options.

Keyphrases